Detalhe da pesquisa
1.
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.
Blood
; 139(2): 256-280, 2022 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34727172
2.
Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.
Int J Clin Oncol
; 27(3): 626-632, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34826011
3.
Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma.
Ann Hematol
; 100(3): 691-698, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33528609
4.
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure.
Hemasphere
; 4(3): e401, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32647803
5.
A Phase 2 Study of Nivolumab Using a Fixed Dose of 40âmg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma.
Hemasphere
; 4(5): e480, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33062947
6.
Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naïve patients.
Leuk Lymphoma
; 60(9): 2316-2319, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30712423